Read about recent events, essential information and the latest community news.
by Fajar Dumadi, BSc Regulatory Program Specialist ISCT Head Office . The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) hosted Read more...
Monday, January 9, 2023 (Toronto, ON) – Viral vectors are critical components in the manufacturing of cell and gene therapies, but their production is currently a key bottleneck and cost driver. CCRM, Read more...
Recently, Eutilex, a partner of GenScript ProBio, announced MFDS clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations Read more...
Sponsored Article Provided by Thermo Fisher Thermo Fisher Scientific Patheon Translational Services facility in San Diego The advanced therapies field is expected to grow at an Read more...
Endotoxin Testing and Validation by Sufira Kiran, DCLS, BS, MLS(ASCP) CM Associate Director, Quality Assurance Uthealth Science Center Houston, TX Bacterial Read more...
by Kara Wacker , MBA, RAC Strategic Planning Administrator Foundation for the Accreditation of Cellular Therapy (FACT) "Great things in business are never done Read more...
ISCT Asia Regional Early Stage Professionals (ESP) Subcommittee Expanding the collaboration network to promote our clinical translation and successful services of cell and gene therapies Read more...
From the President’s Desk: Cell and Gene Therapies and air travel Closer than you think Jacques Galipeau, MD FRCP(C) President, ISCT Don and Marilyn Anderson Professor in Oncology Read more...
by Michele Sugrue MS, MT(ASCP)SBB Remaining open-minded and maintaining objectivity are goals to which I strive in both my personal and professional life. During a heated political discussions Read more...
Interviewed by: Ashley Krull, Ph.D. Telegraft Contributing Editor Mayo Clinic Rochester Rochester, United States Featured Member: Jennifer Hollands Government and Academic Liaison Cell Therapies Read more...